Distinguished in Metastatic Brain Tumor

Dr. Randy L. Jensen

Neurosurgery
University Of Utah Surgical Services
50 N Medical Dr, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Metastatic Brain Tumor
University Of Utah Surgical Services
50 N Medical Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Randy Jensen is a Neurosurgery provider in Salt Lake City, Utah. Dr. Jensen is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Meningioma, Glioma, Glioblastoma, Awake Craniotomy, and Rhizotomy. Dr. Jensen is currently accepting new patients.

His clinical research consists of co-authoring 135 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurosurgery
Licenses
Neurological Surgery in UT
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
View 8 Less Insurance Carriers -

Locations

UNIVERSITY OF UTAH SURGICAL SERVICES
50 N Medical Dr, Salt Lake City, UT 84132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation
Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation
Enrollment Status: Recruiting
Publish Date: June 13, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma
A Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody in Patients With Recurrent or Progressive Glioblastoma
Enrollment Status: Not_yet_recruiting
Publish Date: October 12, 2022
Intervention Type: Biological
Study Drug: C5252
Study Phase: Phase 1
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study
Enrollment Status: Completed
Publish Date: February 25, 2019
Intervention Type: Drug, Procedure
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

135 Total Publications

An analysis of the influence of social determinants of health on treatment and survival among adult patients with high-grade glioma in Utah.
An analysis of the influence of social determinants of health on treatment and survival among adult patients with high-grade glioma in Utah.
Journal: Neuro-oncology practice
Published: October 13, 2025
Similar Doctors
Distinguished in Metastatic Brain Tumor
Dr. Howard Colman
Neurology | Neurosurgery
Distinguished in Metastatic Brain Tumor
Dr. Howard Colman
Neurology | Neurosurgery

University Of Utah Acuity Care Services

175 N Medical Dr, U Of U Neuro Critical Care, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-7575
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Colman is a Neurologist and a Neurosurgery provider in Salt Lake City, Utah. Dr. Colman is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Distinguished in Metastatic Brain Tumor
Dr. Joe S. Mendez
Neurosurgery | Neurology
Distinguished in Metastatic Brain Tumor
Dr. Joe S. Mendez
Neurosurgery | Neurology

University Of Utah Acuity Care Services

50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-2121
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joe Mendez is a Neurosurgery specialist and a Neurologist in Salt Lake City, Utah. Dr. Mendez is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Bone Marrow Aspiration. Dr. Mendez is currently accepting new patients.

Advanced in Metastatic Brain Tumor
Dr. Sarah T. Menacho
Neurosurgery
Advanced in Metastatic Brain Tumor
Dr. Sarah T. Menacho
Neurosurgery

University Of Utah Surgical Services

175 N Medical Dr, University Of Utah Departm, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Sarah Menacho is a Neurosurgery provider in Salt Lake City, Utah. Dr. Menacho is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Astrocytoma, Glioblastoma, Subdural Hematoma, Awake Craniotomy, and Craniectomy. Dr. Menacho is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jensen's expertise for a condition
ConditionClose
View All 12 Distinguished Conditions
View All 8 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile